Drug Trial Radar · NCT04273945
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
935
Actual
Start
Jun 30, 2020
Primary completion
Oct 7, 2025
Study completion Feb 20, 2029
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Feb 18, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with symptomatic pulmonary arterial hypertension (PAH) compared to macitentan 10 mg.
Conditions
- Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mgDrug
Participants will receive macitentan 10 mg film-coated tablets orally.
Macitentan 37.5 mgDrug
Participants will receive macitentan 37.5 mg film-coated tablets orally.
Macitentan 75 mgDrug
Participants will receive macitentan 75 mg film-coated tablets orally.
PlaceboDrug
Participants will receive matching placebo film-coated tablets orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Double-blind Treatment Period: Time to First Clinical Events Committee (CEC)-adjudicated Morbidity or Mortality (M/M) EventsTime frame: Up to 4 years
Locations
274 sites in 42 countries. Site status is shown where the registry gives one.
Mayo Clinic
Phoenix, Arizona
Arizona Pulmonary Specialists, Ltd
Scottsdale, Arizona
Scripps Memorial Hospital
La Jolla, California
USC Keck
Los Angeles, California
Jeffrey S. Sager, MD Medical Corporation
Santa Barbara, California
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Torrance, California
National Jewish Health
Denver, Colorado
Cleveland Clinic
Weston, Florida
Piedmont Healthcare
Atlanta, Georgia
Northside Hospital
Atlanta, Georgia
Advocate Christ Medical Center
Oak Lawn, Illinois
Indiana University
Indianapolis, Indiana
St. Vincent Medical Group, Inc.
Indianapolis, Indiana
University Of Iowa - Hospitals & Clinics
Iowa City, Iowa
Norton Pulmonary Specialists
Louisville, Kentucky
Louisiana State University
New Orleans, Louisiana
University of Michigan
Ann Arbor, Michigan
Troy Beaumont
Troy, Michigan
Washington University School Of Medicine
St Louis, Missouri
Saint Louis University Academic Pavillion
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Reno Heart Institute
Reno, Nevada
Winthrop University Hospital
Mineola, New York
Mount Sinai
New York, New York
Columbia University
New York, New York
Stony Brook University Medical Center
Stony Brook, New York
Duke
Durham, North Carolina
Lindner Clinical Trial Center/Christ Hospital
Cincinnati, Ohio
Integris Baptist Office
Oklahoma City, Oklahoma
The Oregon Clinic Pulmonary West
Beaverton, Oregon
The Oregon Clinic
Portland, Oregon
Oregon Health And Science University
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Allegheny General Hospital of Research
Pittsburgh, Pennsylvania
Lankenau Medical Center
Wynnewood, Pennsylvania
AnMed Health
Anderson, South Carolina
UT Southwestern Medical Center
Dallas, Texas
Baylor College of Medicine (BCM) - Baylor Heart Clinic
Houston, Texas
Baylor Scott White - Plano
Plano, Texas
San Antonio Methodist TX Transplant Physicians Group
San Antonio, Texas
Showing 40 of 274 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.